Semaglutide for Prediabetes: What to Know
Learn how semaglutide for prediabetes may help support blood sugar balance and weight management. Explore the latest research, safety tips, and clinical guidance.
- Semaglutide is used for the treatment of type 2 diabetes and chronic weight management if deemed to be an eligible candidate based on your health conditions
- In trials, semaglutide helped revert prediabetes to normoglycemia in over 80% of patients. All STEP trials used semaglutide medications manufactured by Novo Nordisk.
- It works by improving insulin function, reducing glucagon, and supporting weight loss
- Clinical success is highest when combined with diet, exercise, and stress management
- Always consult a licensed provider before starting treatment
Prediabetes affects more than 1 in 3 adults in the U.S. and raises the risk of developing type 2 diabetes, cardiovascular disease, and other chronic illnesses. While diet and exercise remain foundational, new evidence suggests that medications like semaglutide may offer additional support.
Though not FDA-approved specifically for prediabetes, semaglutide is being studied for its ability to reverse impaired glucose regulation and improve metabolic health in at-risk individuals.
What Is Prediabetes?
Prediabetes is a state where blood glucose levels are elevated but not high enough to qualify as type 2 diabetes:
- Fasting glucose: 100–125 mg/dL
- A1C: 5.7–6.4%
- Post-meal glucose (2 hours): 140–199 mg/dL
Without intervention, up to 70% of prediabetics may develop full diabetes within 5 years. Early strategies are key.
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist that mimics natural incretin hormones. Its metabolic actions include:
- Stimulating insulin secretion when glucose is elevated
- Reducing glucagon levels to lower fasting glucose
- Slowing gastric emptying and increasing satiety
- Acting on the brain to suppress appetite
These effects support both blood sugar control and weight loss, making semaglutide a strong candidate for prediabetes care.
{{primary-cta}}
Semaglutide for Prediabetes: What the Research Shows
Glycemic Improvements
In a major pooled analysis from the STEP trials, up to 89% of participants with prediabetes reverted to normoglycemia after 68 weeks of semaglutide therapy.
- HbA1c reduction: 0.3–0.4%
- Fasting glucose drop: up to 8.5 mg/dL
- Insulin resistance (HOMA-IR): significantly reduced
In the STEP 8 head-to-head trial, semaglutide showed superior reversal of prediabetes vs. liraglutide (89.5% vs. 64.9%).
Weight Loss Synergy
Semaglutide's metabolic effects are closely tied to body weight reduction. In the STEP 1 trial:
- Participants lost ~15% of body weight on average
- 85%+ achieved ≥5% weight loss
- These changes correlated with improved insulin sensitivity and glycemic normalization.
How Semaglutide Is Used
Dosing
- Begin at 0.25 mg/week, titrating to 2.4 mg/week (Wegovy®) or 1–2 mg/week (Ozempic®)
Administration
- Subcutaneous injection (abdomen, thigh, upper arm)
- Oral option available (Rybelsus®) for those avoiding needles
Your licensed healthcare provider will determine the optimal format and schedule.
Semaglutide and Lifestyle: A Synergistic Approach
Semaglutide works best alongside daily health strategies, such as:
- Whole-food nutrition: Emphasize fiber, lean proteins, and unprocessed carbs
- Exercise: At least 150 min/week of moderate aerobic activity
- Stress & sleep optimization: Both affect insulin action and inflammation
- Monitoring: Regular checks of glucose, weight, and labs are essential
Side Effects and Safety
Most Common (temporary)
- Nausea
- Diarrhea or constipation
- Fatigue or bloating
Rare but Serious
- Pancreatitis
- Gallbladder disease
- Thyroid tumors in at-risk individuals (MEN 2, medullary thyroid carcinoma)
Not approved for pregnancy or breastfeeding. Always disclose full medical history before starting.
Cost and Access
Price Range
- Without insurance: $900–$1,500/month for Novo Nordisk-manufactured semglutide medications
- The range mentioned above is accurate at the time of publishing of the blog but is subject to change. It also varies by brand, dosage, and pharmacy.
Saving Tips
- Manufacturer savings cards
- Online pharmacy price comparisons
- Platforms like Eden offer flat-rate pricing and access to licensed providers
How Eden Supports Prediabetes Care
Eden streamlines GLP-1 access by offering:
- Online consultations with licensed providers
- Treatment plans for prediabetes if assessed to be eligible for medications
- Support for dosing, side effects, and long-term goals
If deemed appropriate, Eden-affiliated providers prescribe FDA-approved semaglutide via trusted U.S. pharmacies.
{{primary-cta}}
Final Thoughts
Though not FDA-approved for prediabetes, semaglutide has shown strong evidence of reversing early glucose abnormalities and reducing the risk of type 2 diabetes when paired with lifestyle changes. Results from the STEP trials show that the FDA-approved versions of semaglutide helped the majority of patients normalize blood sugar and significantly reduce body weight.
If you've struggled to manage prediabetes through lifestyle alone, consult a licensed medical provider. Eden can help you explore safe, science-backed options.
Disclaimer
This article is for educational purposes only and does not replace medical advice. Semaglutide should only be used under the care of a licensed healthcare provider. Eden connects individuals with clinicians who may prescribe GLP-1 medications post-assessment if you are considered an eligible candidate. Eligibility is not guaranteed.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by state-licensed pharmacies. Please consult a licensed healthcare provider before making any medical decisions.
Frequently asked questions
No, but it may be prescribed if deemed appropriate by an independent, licensed healthcare provider, if so determined.
Yes. Over 80% of participants in STEP trials achieved normal glycemia after 68 weeks.
It depends. Some patients use it short-term; others benefit from longer use.
Absolutely. Diet, activity, and stress control amplify semaglutide's benefits.
A licensed medical provider will assess your health and help determine if semaglutide is appropriate.
Blog Components

References
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2022). Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obesity and Metabolism, 25(1), 18–35. https://doi.org/10.1111/dom.14863
Chapelsky, S., Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P., Wallenstein, S. O. R., & Roux, C. W. L. (2022). Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults With Overweight/Obesity in the STEP 1 Trial. Canadian Journal of Diabetes, 46(7), S4–S5. https://doi.org/10.1016/j.jcjd.2022.09.012
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P., Wallenstein, S. O. R., & Roux, C. W. L. (2022). Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care, 45(10), 2396–2405. https://doi.org/10.2337/dc21-1785
Rosenstock, J., Garvey, W. T., Goldman, B., Khalid, U., Sørrig, R., & Rubino, D. (2022). 1413-P: Semaglutide 2.4 mg Improved Glucose Metabolism and Reverted Prediabetes to Normoglycemia in Adults with Overweight/Obesity vs. Liraglutide 3.0 mg (STEP 8). Diabetes, 71(Supplement_1). https://doi.org/10.2337/db22-1413-p
















